Selective DNA-PKcs inhibition extends the therapeutic index of localized radiotherapy and chemotherapy
Potentiating radiotherapy and chemotherapy by inhibiting DNA damage repair is proposed as a therapeutic strategy to improve outcomes for patients with solid tumors. However, this approach risks enhancing normal tissue toxicity as much as tumor toxicity, thereby limiting its translational impact. Using NU5455, a newly identified highly selective oral inhibitor of DNA-dependent protein kinase catalytic subunit (DNA-PKcs) activity, we found that it was indeed possible to preferentially augment t...Expand abstract
- Publication status:
- Peer review status:
- Peer reviewed
- Copyright holder:
- Willoughby et al.
- Copyright date:
- Rights statement:
- © 2020, Willoughby et al. This is an open access article published under the terms of the Creative Commons Attribution 4.0 International License.
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record